Fragile X Syndrome Therapeutics Drugs and Companies Pipeline Review, H2 2017Posted by Miller Pit on September 25th, 2017 Summary Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome Pipeline Review, H2 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and lanuage delay and intellectual disability. Browse Detail Report With TOC @https://www.hexareports.com/report/fragile-x-syndrome-pipeline-review-h2-2017 Report Highlights Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Request A Sample copy of This Report @ https://www.hexareports.com/report/fragile-x-syndrome-pipeline-review-h2-2017/request-sampl Scope
Reasons To Buy
About Us: Contact Information: Like it? Share it!More by this author |